Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness.
Infect Control Hosp Epidemiol
; 43(10): 1488-1491, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-1428666
ABSTRACT
We evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Veterans
/
Drug-Related Side Effects and Adverse Reactions
/
COVID-19
Type of study:
Experimental Studies
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Infect Control Hosp Epidemiol
Journal subject:
Communicable Diseases
/
Nursing
/
Epidemiology
/
Hospitals
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS